Daikin has been a world leader in the development, manufacture and sales of fluoropolymers and chemistry since 1924 . Headquartered in Osaka, Japan, Daikin is renowned for innovation, quality and commitment. As the world changes, Daikin is meeting the challenges with technology that makes a difference. We have in the forefront of the fluorocarbon industry is not just constant innovation in the products we develop, but the service and support behind them. Daikin’s fluoropolymers and chemicals, with their wide range of unique properties and Daikin’s products area ideally suited for use in aerospace, architecture, automotive, consumer cookware, energy storage, filtration, home goods, industry, medical, nonwovens, optics & displays, paper & packaging, oil & gas, renewable energy, semiconductor, textile & fabric treatments and wire & cable.

Since 1949, Combe brands have been part of people’s most personal moments. When a man faces his first gray hairs in the mirror — or a woman wonders how to care for the most intimate area of her body — Combe brands are here to help people feel like themselves again: Confident. Comfortable. Looking and feeling their best. We put people’s personal care needs at the center of every thing we do. These aren’t niche needs. They are universal needs, but often kept private. We respect that. At Combe, instead of shying away from these very personal Personal Care problems, we aim to solve them. We believe that’s the right thing to do for people and the smart thing to do for business. Remaining true to our consumer-oriented innovation and marketing platform, Combe markets a portfolio of established brands that include Just for Men, Vagisil, and Sea-Bond in major international markets and Aqua Velva, Lectric Shave, and Brylcreem in the U.S. and Canada. Building upon its success in the United States, Combe has grown steadily in international markets over the last almost four decades, and generates approximately one-third of its revenues from markets outside of the U.S. and Canada including the United Kingdom, Spain, Italy, Australia, Canada, Mexico, and Brazil. The company has transitioned to its third generation of Combe family leadership, under the direction of Keech Combe Shetty and Akshay Shetty.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. For more information, visit www.deciphera.com.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or follow us at @agenus_bio. Our Community Guidelines are available at our website and at: https://agenusbio.com/community-guidelines/

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health. Our team works collaboratively and relentlessly to advance our therapies with the goal of improving the lives of patients, their families, and their caregivers. Radius was founded in 2003 and has locations in Boston, Massachusetts, and Wayne, Pennsylvania. If you think you have the same passion and commitment we have, check out www.radiuspharm.com.

We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.

SK Life Science, Inc., a U.S. subsidiary of SK Biopharmaceuticals, is committed to accelerating the development of innovative treatments for central nervous system (CNS) disorders and oncology. Both companies are a part of SK Group, one of the largest conglomerates in Korea, a global leader in energy, chemical, semiconductor and telecommunications industries, and one of TIME’s 100 Most Influential Companies of 2023. SK Life Science, Inc., is headquartered in Paramus, New Jersey. SK Life Science and SK Biopharmaceuticals have eight compounds in development globally for the treatment of CNS disorders including epilepsy, attention-deficit hyperactivity disorder, schizophrenia, bipolar disorder, and oncology among others. For more information, please visit https://www.sklifescienceinc.com/innovation/#/pipeline. View our community guidelines here: bit.ly/447WI1A

Simoniz USA is headquartered in Bolton, CT with operations predominately in the eastern half of the United States and distributes products both nationally and internationally. The company manufactures a diverse product line covering a broad spectrum of markets including the commercial vehicle washing, professional detailing, retail vehicle appearance, and janitorial/ institutional cleaning. Our floor finishes, disinfectants, waxes, and all-purpose cleaners are widely used in hospitals, nursing homes, food service establishments, manufacturing plants, school systems and the hospitality industry. In new car dealerships, Simoniz offers several different programs such as "GlassCoat"​, MotoTect, and PDRPlus.

Originally founded in 1860 as Ames Chemical Company, the silver refining plant, was sold to GAF Corporation in the late 1960s, and was subsequently purchased by the Ames Goldsmith Corporation in 1979. Ames Goldsmith’s plant has been in continuous operation as a silver refiner and fabricator for nearly 150 years. Today, with an annual silver consumption well in excess of 85 million troy ounces, we are one of the largest integrated silver fabricators in the world. We’ve been recycling silver for nearly a century and a half, making the most of silver – a vital resource for industry, medicine, photography, electronic components, and manufactured consumer products. Ames Goldsmith’s expertise in customizing its standard materials evolved into developing new materials to meet the needs of the continually advancing precious metals products markets including automotive, aerospace, medical, electrical, renewable energy, and electronics. With locations in the USA, UK, and Asia, the recent business diversification includes expansion of the North America and Asia metal powder business units (2013), the acquisition of Ceimig Limited (2015), and the integration of Colonial Metals Industries under the Ames Goldsmith Corporation umbrella in 2017. Ames Goldsmith remains a vibrant testimony to the vision of Merritt Ames, who established a thriving company by reclaiming silver. The current company carries on the tradition of dedication to innovative technology and exceptional customer service. At Ames Goldsmith, we pride ourselves on our ability to work with our customers to meet their unique application requirements. To this end, Ames Goldsmith has become very efficient at modifying our standard materials and developing new materials to meet the changing needs of an ever-evolving marketplace.